TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04920890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency therapy with manual therapy
Description: Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
Study: NCT05235659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules
Description: Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules and experimental condition My coach
Description: Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules and experimental module Who am I and where do I belong?
Description: Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers.
Study: NCT05364190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study: NCT04977193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY011
Description: CAR-T
Study: NCT05209425

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Study: NCT05235659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules and experimental modules Who am I and where do I belong? and My coach
Description: Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules.
Study: NCT06167239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques
Description: New techniques to train inspiratory muscles in mechanically ventilated patients
Study: NCT05851339

Intervention type: OTHER
Intervention: SF- 36 Questionnaire
Description: applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
Study: NCT05020782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: INTERVENTION DRUG: BELIMUMAB 10 MG/KG
Study: NCT06282510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Iodine Topical
Description: Topical intranasal povidone iodine (10%) twice daily for 5 days
Study: NCT05235659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules and experimental module You are safe here
Description: Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic modules and experimental modules You are safe here and My coach
Description: Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules.
Study: NCT05036135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via dry powder inhalation
Study: NCT06176547

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: Blood glucose in last 3 months
Study: NCT05199753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously
Study: NCT06342752

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
Study: NCT05199753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An Anti-PD-1 Antibody
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An Anti-PD-1 Antibody
Description: Administered intravenously
Study: NCT05006066

Intervention type: OTHER
Intervention: Temporal Summation
Description: 4 type of stimulations applied on the right arm
Study: NCT05150626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablets, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablets, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablets, oral
Study: NCT06342752

Intervention type: OTHER
Intervention: Throat swabs
Description: A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.

Intervention type: OTHER
Intervention: Placental samples
Description: After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.

Intervention type: OTHER
Intervention: Vaginal swab
Description: A vaginal swab will be taken before birth for microbiome analysis.

Intervention type: OTHER
Intervention: Endotracheal aspirates
Description: Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
Study: NCT05201261

Intervention type: DEVICE
Intervention: ltrasonic measure
Description: In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
Study: NCT05472402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LADIES online intervention (R33 phase)
Description: Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LADIES online control (R33 phase)
Description: Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
Study: NCT04894071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102
Description: Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.
Study: NCT04387734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrevus will be administered following the FDA's regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platform
Description: The applications of the platform DMTs will follow the FDA-approved regulations.
Study: NCT06068439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
Study: NCT06512623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoadsoprtion
Description: The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge will be measured.
Study: NCT05489536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A web/smartphone-based lifestyle program package
Description: There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring
Study: NCT05389436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory care
Description: The surgery is performed in ambulatory setting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient care
Description: The surgery is performed during inpatient care
Study: NCT05723133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Description: Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Description: Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
Study: NCT05672927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine, 2 doses alternate timing
Description: Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
Study: NCT04829539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive BBT-CI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive HEAL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05672927

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine, 3 doses standard timing
Description: This will be the comparison group for the 2-dose group.
Study: NCT06023849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD insertion
Description: Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD insertion
Description: Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
Study: NCT04731584

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
Study: NCT04829539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05910918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Care Nurses' Training Package
Description: For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Nurses' Training Package
Description: For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
Study: NCT05299164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 1
Description: Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 2
Description: Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 3
Description: Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 4
Description: Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study: NCT06058416

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.
Study: NCT04830501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00434
Description: Once daily \[QD\], 28 days/cycle.
Study: NCT06131385

Intervention type: DRUG
Intervention: intravenous thrombolysis
Description: Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
Study: NCT05611359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation
Description: Thermal hepatic ablation Combined with Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy
Study: NCT05143762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: patients will receive dexamethasone 0.5mg/kg IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: patients will receive placebo 10 ml normal saline IV.
Study: NCT06406686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Description: Durable block across the cavotricuspid isthmus by radiofrequency ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Description: Durable block across the cavotricuspid isthmus by radiofrequency ablation.